Abstract
Background
The 12-month follow-up (F/U) efficacy of CBA PVI performed at community hospitals for treatment of symptomatic paroxysmal and persistent atrial fibrillation (AF) is unknown. This study determined the 12-month efficacy of pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) performed at community hospitals with limited annual case numbers.
Methods
This registry study included 983 consecutive patients (pts) from 19 hospitals, each with an annual procedural volume of < 100 PVI procedures/year. Pts underwent CBA PVI for paroxysmal AF (n = 520), persistent AF (n = 423), or redo PVI (n = 40). The primary endpoint was frequency of documented recurrent AF, the occurrence of atrial flutter or tachycardia following a 90-day period after the index ablation and up to 12 months. The frequency of repeat ablation was determined.
Results
Isolation of all PVs was documented in 98% of pts at the end of the procedure. Twelve-month F/U data could be obtained in 916 pts. A 24-h ECG registration was performed in 641 pts (70.0%); in 107 pts (16.7%) of them, recurrent AF was documented. The primary endpoint was met in 193 F/U pts (21.1%). It occurred in 80/486 F/U pts with paroxysmal AF (16.4%), and in 107/390 F/U pts with persistent AF (27.4%). Redo PVI was performed in 71 pts (7.8%), and atrial flutter ablation was performed in 12 pts (1.4%).
Conclusions
CBA PVI for paroxysmal or persistent AF can be performed at community hospitals with adequate rates of 12-month symptom freedom and arrhythmia recurrence. The study was registered at the German register of clinical studies (DRKS00016504).
Similar content being viewed by others
References
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.
Van Belle Y, Janse P, Rivero-Ayerza MJ, et al. Pulmonary vein isolation using an occluding cryoballoon for circumferential ablation: feasibility, complications, and short-term outcome. Eur Heart J. 2007;28:2231–7.
Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Artic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61:1713–23.
Kuck KH, Brugada J, Fürnkranz A, et al. FIRE and ICE Investigators Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374:2235–45.
Lemes C, Wissneer E, Lin T, et al. One-year clinical outcome after pulmonary vein isolation in persistent atrial fibrillation using the second-generation 28 mm cryoballoon: a retrospective analysis. Europace. 2016;18:201–5.
Providencia R, Defaye P, Lambiase PD, et al. Results from a multicentre comparison of cryoballoon vs radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? Europace. 2017;19:48–57.
Hoffmann E, Straube F, Wegscheider K, et al. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace. 2019;21:1313–24.
Chierchia GB, Di Giovanni G, Ciconte G, et al. Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: 1-year follow-up. Europace. 2014;16:639–44.
Metzner A, Reissmann B, Rausch P, et al. One-year clinical outcome after pulmonary vein isolation using the second-generation 28 mm cryoballoon. Circ Arrhythm Electrophysiol. 2014;7:288–92.
Ciconte G, Ottaviano L, de Asmundis C, et al. Pulmonary vein isolation as index procedure for persistent atrial fibrillation: one-year clinical outcome after ablation using the second-generation cryoballoon. Heart Rhythm. 2015;12:60–6.
Reddy VY, Sediva L, Petru J, et al. Durability of pulmonary vein isolation with cryoballoon ablation: results from the Sustained PV Isolation with Arctic Front Advance (SUPIR) study. J Cardiovasc Electrophysiol. 2015;26:493–500.
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305–15.
Heeger CH, Wissner E, Knoll M, et al. Three-year clinical outcome after 2nd-generation cryoballoon-based pulmonary vein isolation for the treatment of paroxysmal and persistent atrial fibrillation — a 2-center experience. Circ J. 2017;81:974–80.
Hoffmann R, Parade U, Bauerle HJ, et al. Safety and acute efficacy of cryoballoon ablation for atrial fibrillation at community hospitals. Europace. 2021;21:1744–50.
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275–444.
Kuck K, Böcker D, Chun J, et al. Qualitätskriterien zur Durchführung der Katheterablation von Vorhofflimmern. Kardiologe. 2017;11:161–82.
Verma A, Kilicaslan F, Pisano E, et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation. 2005;112:627–35.
Nery P, Belliveau D, Nair GM, et al. Relationship between pulmonary vein reconnection and atrial fibrillation recurrence: a systematic review and meta-analysis. J Am Coll Cardiol EP. 2016;2:474–83.
Martins RP, Galand V, Cesari O, et al. The second generation cryoballoon has improved durable isolation of left but not right pulmonary veins: new insights from a multicenter study. Europace. 2018;20:1115–21.
Verma A, Jiang C, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–22.
Fichtner S, Sparn K, Reents T, et al. Recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation: is repeat pulmonary vein isolation enough? A prospective, randomized trial. Europace. 2017;17:1371–5.
Tilz RR, Heeger CH, Wick A, et al. Ten-year clinical outcome after circumferential pulmonary vein isolation utilizing the Hamburg approach in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2018;11:e005250.
Bordignon S, Furnkranz A, Perrotta L, et al. High rate of durable pulmonary vein isolation after second-generation cryoballoon ablation: analysis of repeat procedures. Europace. 2015;17:725–31.
Arbelo E, Brugada J, Blomström-Lundqvist C, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation long-term registry. Eur Heart J. 2017;38:1303–16.
Duytschaever M, Demolder A, Phlips T, et al. Pulmonary vein isolation with vs without continued antiarrhythmic drug treatment in subjects with recurrent atrial fibrillation (POWDER EF) results from a multicenter randomized trial. Eur Heart J. 2018;39:1429–37.
Heeger CH, Wissner E, Mathew S, et al. Once isolated, always isolated? Incidence and characteristics of pulmonary vein reconduction after second-generation cryoballoon-based pulmonary vein isolation. Circ Arrhythm Electrophysiol. 2015;8:1088–94.
Nimptsch U, Mansky T. Hospital volume and mortality for 25 types of inpatient treatment in German hospitals: observational study using complete national data from 2009 to 2014. BMJ Open. 2017;7:e016184. https://doi.org/10.1136/bmjopen-2017-016184.
Okishige K, Aoyagi H, Nishimura T, et al. Left phrenic nerve injury during electrical isolation of left-sided pulmonary veins with the second-generation cryoballoon. Pacing Clin Electrophysiol. 2017;40:1426–31.
Tokuda M, Yamashita S, Sato H, et al. Long-term course of phrenic nerve injury after cryoballoon ablation of atrial fibrillation. Sci Rep. 2021;11:6226. https://doi.org/10.1038/s41598-021-85618-3.
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–86.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Ethical approval was obtained by the Ärztekammer Niedersachsen and subsequently by the local ethical committees of each federal state that participated in the study.
Conflict of interest
Dr. Bauerle reports speaker fees and consulting fees by Medtronic and Boston Scientific, both companies providing medical supply for pulmonary vein ablation procedures. All other authors do not have any conflicts of interest to be disclosed.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Michaelsen, J., Parade, U., Bauerle, H. et al. Twelve-month efficacy of second-generation cryoballoon ablation for atrial fibrillation performed at community hospitals: results of the German register on cryoballoon ablation in local hospitals (regional). J Interv Card Electrophysiol 66, 417–425 (2023). https://doi.org/10.1007/s10840-022-01331-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-022-01331-9